Review of guidelines on the treatment of metastatic renal cell carcinoma
暂无分享,去创建一个
[1] J. Knox,et al. Management of kidney cancer: Canadian Kidney Cancer Forum Consensus Statement. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[2] J. Knox,et al. Canadian kidney cancer forum 2008. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[3] G. Bjarnason,et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[4] J. Marrero,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[5] B. Rini,et al. A population‐based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer , 2009, Cancer.
[6] R. Motzer,et al. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. , 2008, Clinical genitourinary cancer.
[7] M. Kattan,et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma , 2008, Cancer.
[8] S. McKenna,et al. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. , 2008, Biochemical Society transactions.
[9] J. Patard,et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. , 2008, European urology.
[10] R. Motzer,et al. Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[11] N. Munshi,et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.
[12] R. Sylvester,et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.
[13] R. Prentice. Use of the logistic model in retrospective studies. , 1976, Biometrics.
[14] Lorenzo Marconi,et al. Guidelines on Renal Cell Carcinoma , 2007 .